Abstract:The vectorial secretion of bile salts from blood into bile is a major driving force for bile formation. The basolateral hepatocyte membrane extracts bile salts from sinusoidal blood via Na(+)-dependent and Na(+)-independent membrane transporters. Na(+)-dependent uptake of bile salts is mediated by the Na(+)-taurocholate co-transporting polypeptide, a 51-kDa protein that is exclusively expressed in hepatocytes. Na(+)-independent uptake of bile salts is mediated by the organic anion transporting polypeptides, a superfamily of multispecific bile salt and amphipathic substrate transporters. Within the hepatocyte, bile salts are bound to cytosolic proteins and traverse the cell mainly by diffusion. Transport across the canalicular membrane is the rate-limiting step in overall hepatocellular bile salt excretion and is mediated by the bile salt export pump (BSEP), a homologue of the P-glycoproteins or multidrug resistance gene products. BSEP is a vulnerable target for inhibition by estrogen metabolites, drugs such as cyclosporine A, and abnormal bile salt metabolites, all of which can cause retention of bile salts and consequently intrahepatic cholestasis. Canalicular efflux of divalent sulfated or glucuronidated bile salts is mediated by the multidrug resistance protein 2 (MRP2), which is strongly decreased in cholestasis. Decreased MRP2 expression leads to compensatory increases in the basolateral expression of MRP1 and MRP3, which mediate the sinusoidal efflux of divalent bile salt conjugates and other organic anions. Thus, the hepatocyte can regulate expression levels of individual bile salt transporters during cholestasis to evade hepatotoxic injury.

The pathophysiology of cholestasis with special reference to primary biliary cirrhosis

Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis

Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics

The neglected biliary mucus and its phosphatidylcholine content: a putative player in pathogenesis of primary cholangitis-a narrative review article

The role of enterohepatic circulation of bile acids and intestinal microbiota in the pathogenesis and treatment of cholestatic liver disease

Primary biliary cholangitis: pathogenesis and therapeutic opportunities

Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC)

Bile acid-mediated signaling in cholestatic liver diseases

Central role for cholangiocyte pathobiology in cholestatic liver diseases

Novel and emerging therapies for cholestatic liver diseases

Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis

Mechanisms of Fibrosis in Primary Biliary Cholangitis

Novel therapeutic targets in primary biliary cirrhosis

New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease

Rationality of medication based on the "ascending" pathophysiology of cholestatic liver disease

Primary biliary cholangitis: molecular pathogenesis perspectives and therapeutic potential of natural products

Hepatic transport of bile salts

Comprehensive Review of Molecular Mechanisms during Cholestatic Liver Injury and Cholangiocarcinoma

Molecular mechanisms of cholangiopathy in primary biliary cirrhosis

Experimental Evidence on the Immunopathogenesis of Primary Biliary Cirrhosis

ABCB4/MDR3 in health and disease - at the crossroads of biochemistry and medicine